Snigdha Banerjee, Affan A Ansari, Sunil P Upadhyay, Daniel J Mettman, Jamie R Hibdon, Mohiuddin Quadir, Pratyusha Ghosh, Anjali Kambhampati, Sushanta K Banerjee
Cells 2024 Feb 25The aberrant glycosylation is a hallmark of cancer progression and chemoresistance. It is also an immune therapeutic target for various cancers. Tunicamycin (TM) is one of the potent nucleoside antibiotics and an inhibitor of aberrant glycosylation in various cancer cells, including breast cancer, gastric cancer, and pancreatic cancer, parallel with the inhibition of cancer cell growth and progression of tumors. Like chemotherapies such as doxorubicin (DOX), 5'fluorouracil, etoposide, and cisplatin, TM induces the unfolded protein response (UPR) by blocking aberrant glycosylation. Consequently, stress is induced in the endoplasmic reticulum (ER) that promotes apoptosis. TM can thus be considered a potent antitumor drug in various cancers and may promote chemosensitivity. However, its lack of cell-type-specific cytotoxicity impedes its anticancer efficacy. In this review, we focus on recent advances in our understanding of the benefits and pitfalls of TM therapies in various cancers, including breast, colon, and pancreatic cancers, and discuss the mechanisms identified by which TM functions. Finally, we discuss the potential use of nano-based drug delivery systems to overcome non-specific toxicity and enhance the therapeutic efficacy of TM as a targeted therapy.
Snigdha Banerjee, Affan A Ansari, Sunil P Upadhyay, Daniel J Mettman, Jamie R Hibdon, Mohiuddin Quadir, Pratyusha Ghosh, Anjali Kambhampati, Sushanta K Banerjee. Benefits and Pitfalls of a Glycosylation Inhibitor Tunicamycin in the Therapeutic Implication of Cancers. Cells. 2024 Feb 25;13(5)
PMID: 38474359
View Full Text